OSTX

OS Therapies

--(--)

Market Open: --

--(--)

Post-Market: --

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About OSTX

Os Therapies Incorporated

A clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors

Industry

Biological Technology

Established Date

04/12/2018

Listing Date

08/01/2024

Exchange

American Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.ostherapies.com

Security Type

Common stock

Office address

15825 Shady Grove Road, Suite 135, Rockville, Maryland 20850

Business

Introduction

OS Therapies Incorporated was incorporated in Delaware on April 12, 2018. The Company is a clinical-stage biopharmaceutical company focused on the identification, development and commercialization of osteosarcoma and other solid tumor treatments. They are currently seeking to respond to the call for new therapies with their main core product candidate, OST-HER2 (also known as OST31-164). They intend to use this product candidate to expand their pipeline from osteosarcoma to other solid tumors with the same mechanism of recurrence, including breast, esophageal and lung cancer.

Company Financials

EPS

OSTX has released its 2024 Q4 earnings. EPS was reported at -0.24, versus the expected -0.14, missing expectations. The chart below visualizes how OSTX has performed over recent quarters, highlighting trends in earnings surprises.